Michael Born is a Technical Development Senior Principal Scientist at Genentech since 2025. They previously worked as a Scientist in Analytical and Formulations Development at InhibRx from 2017 to 2022 and held the position of Principal Scientist-CMC Analytical at Poseida Therapeutics, Inc. from 2024 to 2025. Earlier in their career, Michael served as an Associate Scientist in Analytical Chemistry at La Jolla Biologics, Inc., and was a Research Investigator at San Diego State University from 2008 to 2009. They began their academic journey as a Graduate Student at Northwestern University from 2011 to 2012.
This person is not in any teams
This person is not in any offices